JANONE INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.94 EUR | +2.08% |
|
+4.26% | +503.08% |
| Sales 2022 | 39.61M 36.52M 53.97M | Sales 2023 | - | Capitalization | 2.75M 2.54M 3.75M |
|---|---|---|---|---|---|
| Net income 2022 | 11M 10.14M 14.99M | Net income 2023 | -7M -6.45M -9.54M | EV / Sales 2022 | 0.41 x |
| Net Debt 2022 | 12.02M 11.09M 16.38M | Net Debt 2023 | 416K 384K 567K | EV / Sales 2023 | - |
| P/E ratio 2022 |
0.39
x | P/E ratio 2023 |
-0.28
x | Employees | 5 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 99.07% |
More Fundamentals
* Assessed data
More news
More press releases
More news
| 1 day | +2.08% | ||
| 1 week | +4.26% | ||
| 1 month | -10.91% | ||
| 3 months | +198.48% | ||
| 6 months | +693.52% | ||
| Current year | +503.08% |
1 week
2.82
3.22
1 month
2.605.20
Current year
0.435.20
1 year
0.245.20
3 years
0.247.95
5 years
0.2427.40
10 years
0.2427.40
| Managers | Title | Age | Since |
|---|---|---|---|
Antonios Isaac
CEO | Chief Executive Officer | 71 | 15-04-30 |
Virland Johnson
DFI | Director of Finance/CFO | 64 | 17-08-20 |
Amol Soin
CTO | Chief Tech/Sci/R&D Officer | - | 20-01-28 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Antonios Isaac
CEO | Chief Executive Officer | 71 | 15-04-30 |
Richard Butler
BRD | Director/Board Member | 74 | 15-04-30 |
Nael Hajjar
BRD | Director/Board Member | 40 | 18-07-31 |
| Date | Price | Change |
|---|---|---|
| 24-05-31 | 2.94 | +2.08% |
| 24-05-30 | 2.88 | +1.41% |
| 24-05-29 | 2.84 | +0.71% |
| 24-05-28 | 2.82 | -12.42% |
| 24-05-27 | 3.22 | +14.18% |
Delayed Quote Deutsche Boerse AG, May 31, 2024 at 09:59 am
More quotes
JanOne Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying, acquiring, licensing, developing, partnering, and commercializing novel, no-opioid, and non-addictive therapies to address the large, unmet medical need for the treatment of pain and addiction. Its drug candidate, JAN101, is a patented oral, sustained-release pharmaceutical composition of sodium nitrite that targets poor blood flow to the extremities, such as those with vascular complications of diabetes or Peripheral Artery Disease (PAD) and treats pain. Its drug candidate is a treatment for Peripheral Artery Disease. The Company operates through the Biotechnology segment, which is focused on finding treatments for conditions that cause severe pain and bringing to market drugs with non-addictive pain-relieving properties. The Company is also engaged in providing blockchain-powered technologies through its two platforms: ALT 5 Pay and ALT 5 Prime.
| 1st Jan change | Capi. | |
|---|---|---|
| +43.36% | 54.63B | |
| -5.31% | 39.92B | |
| +14.75% | 26.86B | |
| -12.56% | 26.22B | |
| -22.45% | 18.78B | |
| +25.12% | 12.21B | |
| +0.04% | 12.16B | |
| +26.04% | 11.94B | |
| -11.83% | 10.74B |
- Stock Market
- Equities
- JAN Stock
- 5AR1 Stock
